KPF
VVOS icon

K2 Principal Fund’s Vivos Therapeutics VVOS Stock Holding History

K2 Principal Fund’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,590
Closed -$320K – 362
2021
Q2 		$320K Buy
+2,590
New +$422K 0.03% 294
2021
Q1 		– Sell
-2,056
Closed -$304K – 369
2020
Q4 		$304K Buy
+2,056
New +$375K 0.03% 261

Other funds holding VVOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIA
Avalon Investment & Advisory Houston, Texas $3.65B AUM 0.47% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

K2 Principal Fund's VVOS Position: Q3 2021 in Review

K2 Principal Fund sold out of Vivos Therapeutics (VVOS) in Q3 2021, closing a stake of 2,590 shares — an estimated $320K sold.

K2 Principal Fund first reported a position in VVOS in Q4 2020 and held it in 2 quarters. The position peaked at $320K in Q2 2021. 37 funds tracked by Wall St. Rank hold VVOS as of Q3 2021.

  • K2 Principal Fund reported no remaining Vivos Therapeutics position as of Q3 2021 after selling out during the quarter.
  • K2 Principal Fund sold 2,590 Vivos Therapeutics shares in Q3 2021, an estimated $320K.
  • K2 Principal Fund first reported a position in Vivos Therapeutics in Q4 2020 and held it in 2 quarters.
  • K2 Principal Fund's Vivos Therapeutics position peaked at $320K in Q2 2021.
  • 37 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q3 2021.

Based on K2 Principal Fund's 13F filing for Q3 2021, filed 12 Nov 2021.